2022
DOI: 10.1007/s00113-022-01267-9
|View full text |Cite
|
Sign up to set email alerts
|

Biologische Rekonstruktion von großen Knochendefekten

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…Nonetheless, as described earlier by Hollister and Murphy [238], to routinely establish standardized large-scale multicentre (pre)clinical research efforts, we must first define the goal of BTE and the role that biomaterial implants play in achieving this aim-that is, we must find viable and both clinical and economical approaches to bone regeneration in orthopaedic surgery for long bone defects. In particular, there is limited guidance on the specific surgical indications, the current medico-legal status and reimbursement, and the (large-scale) clinical trials that should be performed [246,247].…”
Section: Three-dimensional-printed Bone Regeneration Scaffolds-quo Va...mentioning
confidence: 99%
“…Nonetheless, as described earlier by Hollister and Murphy [238], to routinely establish standardized large-scale multicentre (pre)clinical research efforts, we must first define the goal of BTE and the role that biomaterial implants play in achieving this aim-that is, we must find viable and both clinical and economical approaches to bone regeneration in orthopaedic surgery for long bone defects. In particular, there is limited guidance on the specific surgical indications, the current medico-legal status and reimbursement, and the (large-scale) clinical trials that should be performed [246,247].…”
Section: Three-dimensional-printed Bone Regeneration Scaffolds-quo Va...mentioning
confidence: 99%
“…Scaffolds fabricated from mPCL alone are known to promote an innate immune response ( Baker et al, 2011 ); however, the subcutaneous implantation of the mPCL-HA composite scaffold resulted—as expected from clinical studies ( Laubach et al, 2023b ; Liodakis et al, 2023 )—in a minimal non-inflammatory response as depicted by the IHC results for all experimental groups. In particular, we observed weak staining of foreign body giant cells with iNOS (M1 macrophage phenotype marker), indicating a balanced host defense to the scaffold-bone graft constructs.…”
Section: Discussionmentioning
confidence: 78%
“…For SGBR, suitable degradation properties of the scaffold and enhancement of bioactivity are best achieved by incorporating ceramic fillers such as hydroxyapatite (HA) ( Bartnikowski et al, 2019 ), which also increase bone-forming potential in vivo ( Chuenjitkuntaworn et al, 2010 ; Ma et al, 2019 ). Biodegradable composite implants made of PCL-HA are approved by the United States Food and Drug Administration (FDA) for bone defect treatment (DePuy Synthes’ TRUMATCH Graft Cage) ( Liodakis et al, 2023 ); however, these implants do not present with a fully interconnected three-dimensional (3D) pore architecture, which is essential for SGBR ( Laubach et al, 2023b ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation